Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
2(18%)
Results Posted
25%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
2
18%
Ph phase_3
1
9%
Ph phase_1
8
73%

Phase Distribution

8

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
8(72.7%)
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (72.7%)
Phase 22 (18.2%)
Phase 31 (9.1%)

Trials by Status

completed873%
terminated19%
recruiting218%

Recent Activity

2 active trials
Showing 5 of 11
completedphase_3

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

NCT05136664
recruitingphase_1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364
recruitingphase_1

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

NCT07250750
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

NCT06122714
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05136664Phase 3

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects

Completed
NCT07228364Phase 1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Recruiting
NCT07250750Phase 1

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

Recruiting
NCT06491550Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Completed
NCT06122714Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Completed
NCT05576623Phase 1

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

Completed
NCT01744704Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

Completed
NCT01378676Phase 2

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT02377362Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Terminated
NCT02454387Phase 1

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

Completed
NCT01211249Phase 2

GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11